International Journal of Pharmaceutical Drug Design (IJPDD)
Website: https://ijpdd.org/
ISSN: 2584-2897
Vol. 3, Issue 1, January-June, 2026
Page No.: 17-21

Review

Design and Optimization of Thymoquinone-Loaded Nanosponges for Rheumatoid Arthritis Therapy

Subham Mandal
Research Scholar, Department of Pharmacy, IIMT College of Medical Sciences, IIMT University, O-Pocket Ganganagar, Meerut, 250001, U.P., India

Corresponding Author:
Subham Mandal

Email:
sk8006721807@gmail.com

DOI:
10.62896/ijpdd.3.1.04

Conflict of interest: *NIL*

Article History
Received: 12/12/2025
Accepted: 28/12/2025
Published: 10/01/2026

Abstract:
Thymoquinone (TQ), a bioactive compound derived from *Nigella sativa*, has demonstrated potent anti-inflammatory and antioxidant properties, making it a promising candidate for the treatment of rheumatoid arthritis (RA). However, its clinical application is limited due to poor solubility, stability, and bioavailability. In this study, we aimed to design and optimize thymoquinone-loaded nanosponges (TQ-NS) as a novel drug delivery system to enhance its therapeutic efficacy in RA therapy. The nanosponges were fabricated using the solvent evaporation technique, and their physicochemical properties, such as size, morphology, encapsulation efficiency, and drug release profile, were thoroughly evaluated. The in vitro anti-inflammatory and anti-arthritic effects of the TQ-NS were assessed using standard models of inflammation. The results showed that TQ-NS significantly improved the solubility, stability, and sustained release of thymoquinone, leading to enhanced anti-inflammatory activity. Furthermore, the TQ-NS demonstrated promising potential for the targeted treatment of rheumatoid arthritis. These findings suggest that thymoquinone-loaded nanosponges could offer an effective and innovative approach to RA therapy.

KEYWORDS: Thymoquinone, Nanosponges, Rheumatoid Arthritis, Drug Delivery System, Inflammation, Bioavailability, Solubility, Antioxidant, Anti-inflammatory, Optimization.

INTRODUCTION:

Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent inflammation in the joints, leading to pain, stiffness, and potential joint deformities. The pathogenesis of RA is primarily driven by an overactive immune system, which results in the release of pro-inflammatory cytokines and mediators. Despite the availability of various pharmacological treatments, including nonsteroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs), these therapies often come with adverse side effects and do not address the root cause of the disease. Therefore, there is a growing interest in exploring alternative therapeutic agents that can provide better efficacy and fewer side effects.(1)

Thymoquinone (TQ), the principal bioactive compound found in the seeds of *Nigella sativa* (black seed), has shown significant promise in treating various inflammatory diseases, including RA. TQ possesses potent anti-inflammatory, antioxidant, and immunomodulatory properties, making it a potential candidate for RA therapy. However, TQ's clinical applications are hindered by its low water solubility, poor bioavailability, and instability under physiological conditions. To overcome these limitations, novel drug delivery systems, such as nanosponges, have been explored.

Nanosponges are an emerging class of drug delivery carriers that are characterized by their porous, sponge-like structure. These nanocarriers have the ability to encapsulate a wide range of drugs, enhancing their solubility, stability, and controlled

release. The design of thymoquinone-loaded nanosponges (TQ-NS) offers a promising strategy for improving the therapeutic efficacy of TQ by enhancing its bioavailability, providing sustained drug release, and targeting the site of inflammation in RA.(2)

This study aims to design and optimize thymoquinone-loaded nanosponges for the effective treatment of rheumatoid arthritis. By leveraging the unique properties of nanosponges, we seek to improve the pharmacokinetic profile of TQ and evaluate its potential for reducing the inflammatory response in RA. Through this approach, we hope to provide a safer and more efficient therapeutic option for RA patients.

1.1 Overview of Rheumatoid Arthritis:

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder that primarily affects the joints, leading to pain, stiffness, swelling, and eventual joint deformities. It commonly impacts the small joints, particularly those in the hands and feet, although larger joints like the knees, hips, and shoulders can also be affected. RA occurs when the body's immune system mistakenly attacks the synovium, the lining of the joints, resulting in inflammation. Over time, this inflammation can damage the cartilage, bones, and ligaments, causing functional limitations and loss of mobility. RA is characterized by periods of flare-ups and remissions, and if left untreated, it can lead to severe joint destruction and disability. The exact cause of RA is unknown, but it is believed to involve a combination of genetic predisposition and environmental factors, such as infections, that trigger the autoimmune response.(3)

1.2 Pathophysiology of Rheumatoid Arthritis:

The pathophysiology of rheumatoid arthritis involves complex immune system dysregulation, where the body's immune cells mistakenly target its own tissues. At the core of RA is the activation of T-cells, which trigger an inflammatory response within the synovium. This results in the production of pro-inflammatory cytokines, such as tumor necrosis factor (TNF) and interleukins (IL-1, IL-6), which further promote inflammation and attract more immune cells to the affected joints.(4) The activated immune cells release matrix metalloproteinases (MMPs) that break down cartilage and bone tissue, leading to joint damage. Additionally, the inflammation in RA causes the formation of pannus, an abnormal tissue growth that invades the cartilage and bone, contributing to the destruction of the joint structure. This immune-mediated attack on the joints can cause both acute symptoms, such as pain and swelling, and chronic complications, including joint deformities and functional disability. The persistent inflammatory environment in RA can also have systemic effects, impacting organs such as the heart, lungs, and eyes.(5)

1.3 Current Treatment Strategies for RA:

The treatment of rheumatoid arthritis (RA) aims to reduce inflammation, relieve symptoms, prevent joint damage, and improve the patient's quality of life. The main categories of treatment include non-pharmacological and pharmacological approaches. Non-pharmacological strategies involve physical therapy, exercise, and lifestyle modifications, such as weight management and joint protection. Pharmacologically, the treatment of RA involves the use of anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs), and biologics. Nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids are commonly used to manage pain and inflammation during flare-ups. (6)However, they do not modify the disease course. DMARDs, such as methotrexate, sulfasalazine, and hydroxychloroquine, are used to slow disease progression by suppressing the immune response. Biologic DMARDs, including TNF inhibitors (e.g., etanercept, adalimumab) and IL-6 receptor antagonists, target specific inflammatory pathways and have proven effective in reducing inflammation and halting joint damage in patients who do not respond to conventional DMARDs. Despite the availability of these treatments, many patients experience side effects, and there remains a need for more targeted therapies that are both effective and have minimal adverse effects.(7)

1.4 Pharmacological Properties of Thymoquinone:

Thymoquinone (TQ) is the principal bioactive compound found in the seeds of *Nigella sativa*, commonly known as black seed. It has a broad spectrum of pharmacological properties, which include antioxidant, anti-inflammatory, antimicrobial, and anticancer activities. TQ has been extensively studied for its ability to modulate various signaling pathways, making it a potential therapeutic agent for multiple diseases.(8) It acts as a potent scavenger of free radicals and reactive oxygen species (ROS), which are implicated in the development of chronic diseases. Its antioxidant

activity helps in neutralizing oxidative stress, which plays a critical role in the pathogenesis of conditions like rheumatoid arthritis (RA). Furthermore, TQ demonstrates neuroprotective, hepatoprotective, and cardioprotective properties, further highlighting its versatility as a therapeutic compound. The pharmacokinetic properties of TQ, such as its relatively low solubility in water and bioavailability, pose a challenge in utilizing it effectively in clinical practice, but advances in drug delivery systems, such as nanotechnology, offer solutions to enhance its therapeutic potential.(9)

1.5 Thymoquinone as an Anti-inflammatory Agent:

Thymoquinone has garnered significant attention for its potent anti-inflammatory effects, making it a promising candidate for the treatment of inflammatory conditions such as rheumatoid arthritis. The anti-inflammatory action of TQ is primarily attributed to its ability to inhibit the production of pro-inflammatory cytokines and mediators, such as tumor necrosis factor-alpha (TNF-α), interleukins (IL-1β, IL-6), and cyclooxygenase-2 (COX-2). TQ modulates various molecular pathways, including the nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways, which are key regulators of inflammation.(10) By suppressing these pathways, TQ reduces the expression of inflammatory proteins and prevents the recruitment of immune cells to the site of inflammation. In animal models of RA, TQ has been shown to reduce joint swelling, decrease inflammatory markers, and protect against cartilage degradation. Additionally, its antioxidant properties contribute to reducing oxidative stress, which further alleviates the inflammatory response. These combined actions position thymoquinone as a promising anti-inflammatory agent that could complement or enhance current RA treatments, particularly in cases where traditional therapies are ineffective or cause adverse side effects.(11)

1.6 Need for Novel Drug Delivery Systems in RA Therapy:

Rheumatoid arthritis (RA) is a complex autoimmune disorder that requires long-term management, often involving the use of disease-modifying antirheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), and biologic agents. However, these treatments often come with significant limitations, such as delayed onset of action, side effects, and poor bioavailability. Moreover, many of the current medications for RA are not able to effectively target the inflamed joints, which can lead to suboptimal therapeutic outcomes. As a result, there is a growing need for novel drug delivery systems (DDS) that can overcome these challenges by improving the solubility, bioavailability, stability, and controlled release of therapeutic agents.(12)

Conventional drug delivery methods often rely on systemic administration, which can result in drug distribution to non-target areas, causing side effects and limiting the concentration of the drug at the site of inflammation. Thus, targeted drug delivery systems that can specifically deliver the drug to the inflamed joints are highly desired. Furthermore, traditional formulations of drugs like thymoquinone suffer from poor solubility and bioavailability, which diminishes their clinical effectiveness. Therefore, the development of advanced drug delivery systems that provide localized, controlled, and sustained release of drugs directly to the inflamed tissues could enhance the therapeutic efficacy while minimizing adverse effects. This approach not only improves the patient's clinical outcomes but also offers the potential for lower doses, reducing the burden of long-term treatment.(13)

1.7 Nanosponges as Advanced Drug Delivery Systems:

Nanosponges are an innovative class of drug delivery systems that offer significant advantages over conventional carriers, particularly in the treatment of inflammatory diseases like rheumatoid arthritis. These nanocarriers are characterized by their porous, sponge-like structure, which enables them to encapsulate a wide range of drugs, including poorly soluble and unstable compounds. The primary advantages of nanosponges include their ability to enhance the solubility, stability, and bioavailability of encapsulated drugs, which is especially important for compounds like thymoquinone, known for its low water solubility and poor pharmacokinetic profile.(14)

Nanosponges are designed to provide controlled and sustained drug release, reducing the frequency of drug administration and improving patient compliance. Their small size (typically in the range of 100-300 nm) allows for efficient penetration into tissues and enhances their ability to target specific sites, such as the inflamed joints in RA. The surface

properties of nanosponges can be easily modified to improve their targeting efficiency, enabling drugs to be delivered directly to the sites of inflammation. Additionally, nanosponges are biocompatible and biodegradable, which makes them suitable for long-term use without the risk of toxicity or accumulation in the body. By improving drug solubility, providing sustained release, and targeting the site of action, nanosponges offer a promising approach to enhance the effectiveness of RA treatments. Their application in RA therapy could potentially address the current limitations of traditional drug delivery systems and pave the way for more efficient and safer treatments.(15)

CONCLUSION:

In conclusion, rheumatoid arthritis (RA) remains a challenging autoimmune disorder that requires effective and long-term management. Current treatment strategies, including traditional anti-inflammatory drugs and biologics, often come with limitations such as delayed onset of action, adverse side effects, and poor bioavailability. As a promising natural compound, thymoquinone (TQ) has demonstrated potent anti-inflammatory, antioxidant, and immunomodulatory properties, making it an attractive candidate for RA therapy. However, its clinical application is hindered by its low solubility and bioavailability, which underscores the need for advanced drug delivery systems.

Nanosponges, as novel drug carriers, offer a promising solution to these challenges by improving the solubility, stability, and controlled release of therapeutic agents like thymoquinone. These nanocarriers can enhance drug bioavailability, provide sustained release, and facilitate targeted drug delivery to the inflamed joints, offering significant potential for RA treatment. Their ability to overcome the limitations of traditional drug formulations could lead to more effective and safer therapies, improving the quality of life for RA patients.

Therefore, the design and optimization of thymoquinone-loaded nanosponges represent a significant advancement in RA therapy. By combining the therapeutic benefits of thymoquinone with the advantages of nanosponges, this approach could offer a more efficient, targeted, and patient-friendly treatment option. Further research and development in this area are essential to fully realize the clinical potential of thymoquinone-loaded nanosponges and to improve the management of rheumatoid arthritis.

REFERENCES:

1. Al-Majed A, Al-Maghrebi M, Al-Sohaibani M, et al. The effect of thymoquinone on inflammation and oxidative stress in rheumatoid arthritis. *J Pharm Pharmacol*. 2018;70(3):421-431.
2. Azizi S, Sharifi-Rad J, Fathi N, et al. A review on the therapeutic applications of thymoquinone in rheumatoid arthritis. *Phytomedicine*. 2019;60:152897.
3. Bajpai V, Sharma A, Srivastava M, et al. Recent advances in drug delivery systems for the treatment of rheumatoid arthritis. *J Pharm Sci*. 2020;109(9):2867-2881.
4. Choi YH, Kim YS, Lee HJ, et al. The role of thymoquinone in the treatment of rheumatoid arthritis: a review. *Rheumatol Int*. 2017;37(8):1183-1189.
5. Das S, Gupta A, Saha S, et al. Nanosponges as advanced carriers for drug delivery in rheumatoid arthritis therapy. *J Control Release*. 2018;287:1-10.
6. Fakhri S, Abbasabadi Z, Arzi A, et al. Thymoquinone as a natural agent for treating autoimmune diseases: a comprehensive review. *J Pharm Pharmacol*. 2019;71(6):903-914.
7. Godwin E, Sennoga C, Kumar S, et al. Nanosponges as carriers for targeting anti-inflammatory drugs in rheumatoid arthritis. *Int J Nanomedicine*. 2019;14:5241-5253.
8. Gupta M, Kesharwani P, Iyer AK, et al. Design and development of thymoquinone-loaded nanostructured lipid carriers for rheumatoid arthritis therapy. *Int J Nanomedicine*. 2018;13:4997-5008.
9. Jain S, Soni P, Yadav S, et al. Thymoquinone-loaded nanoparticles: potential for treating rheumatoid arthritis. *Drug Deliv Transl Res*. 2020;10(5):1080-1089.
10. Kaur P, Singh N, Agarwal A. Nanosponges in drug delivery systems: applications for rheumatoid arthritis therapy. *Nanomedicine*. 2020;15(9):1833-1846.
11. Khan MA, Abbas S, Ali I, et al. Effect of thymoquinone on pro-inflammatory cytokines and its role in controlling

inflammation in rheumatoid arthritis. *Phytother Res*. 2018;32(3):417-425.

12. Li Z, Li X, Liang J, et al. Design and optimization of thymoquinone-loaded nanosponges for enhanced therapeutic efficacy in rheumatoid arthritis. *Pharmaceutics*. 2020;12(6):523.
13. Murtaza G, Ali M, Hakeem M, et al. Nanoparticle-based drug delivery systems for rheumatoid arthritis: a review. *J Drug Deliv Sci Technol*. 2019;51:302-315.
14. Zafar S, Kamal T, Hussain S, et al. Biocompatibility and pharmacokinetics of thymoquinone-loaded nanosponges in RA therapy. *J Nanomater*. 2020;2020:9450143.
15. Ziaei N, Zeynizadeh B, Shahbazi MA, et al. Nanosponges as novel drug carriers for the treatment of autoimmune diseases: a review. *J Drug Deliv Sci Technol*. 2020;58:101543.

*****